Trial reportBritish journal of cancer2025
Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial.
Trial report in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoradiotherapy is less tolerable for postoperative locoregional recurrent esophageal squamous cell carcinoma (ESCC).
methodsESCC patients with three or fewer locoregional recurrent lesions after radical surgery were enrolled. Anlotinib (12 mg, d1-14) was administered with radiotherapy (50.4-59.4 Gy) concurrently for two cycles, followed by sequentially for another two cycles. The primary endpoints were objective response rate (ORR) and toxicity.
resultsBetween October 2019 and July 2022, 40 patients were eligible. The ORR was 90.0% (20.0% complete response, 70.0% partial response). The median local failure-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 21.7 (95% CI, 7.839-35.627), 26.4 (95% CI, 17.706-35.028), 12.7 (95% CI, 4.023-21.377), and 29.9 months (95% CI, 18.543-41.323), respectively. Grade 3 adverse events occurred in only two patients (5.0%) who developed hypertension. No grade 4 treatment-related adverse events were observed.
conclusionsThe regimen of radiotherapy combined with anlotinib demonstrated high efficacy with tolerable toxicity in postoperative locoregional recurrent ESCC. This novel regimen provided a selectable treatment strategy for such patients, especially for those who cannot tolerate or refuse chemotherapy. Further randomised controlled trials are warranted. CLINICAL
trial registrationChinese Clinical Trial Registry (ChiCTR1900025752).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.